Taken together these findings provide strong evidence that ERK5 pathway therapeutics may have use in the treatment of melanoma in combination with BRAF-MEK1/2-ERK1/2 pathway inhibitors to overcome intrinsic resistance and hinder or delay some modes of acquired resistance. Here, BRAF is linked to melanoma.